Based on the above findings, it was confirmed that the IGF2BP2-based prognostic scoring model not only helps to assess the prognostic outcomes of patients, but also contributes to an in-depth understanding of the cancer metastasis mechanism, and also provides a profound theoretical basis and scientific foundation for the development of anti-LUAD strategies by targeting IGF2BP2-based m6A modification. This evidence concerns the gene IGF2BP2 and cancer.